Comparing the Expected Benefit of Extra-corporeal-shockwave Therapy (ESWT) Treatment to Standard Care in Treating Diabetic Foot Ulcers
ESWT Treatment of Diabetic Foot VS. Standard Care Trial
1 other identifier
interventional
300
0 countries
N/A
Brief Summary
The purpose of this study is to determine if Extra-corporeal-shockwave Therapy (ESWT) added to standard of care wound therapy significantly improves time to complete wound healing in diabetic foot wounds.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2012
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 4, 2011
CompletedFirst Posted
Study publicly available on registry
December 26, 2011
CompletedStudy Start
First participant enrolled
January 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2015
CompletedDecember 26, 2011
August 1, 2011
1 year
September 4, 2011
December 22, 2011
Conditions
Outcome Measures
Primary Outcomes (1)
healed ulcer
6 months
Study Arms (2)
shock wave therapy, shortened wound healing time
ACTIVE COMPARATORnormal wound care
OTHERstandard of care intervention
Interventions
shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
Eligibility Criteria
You may qualify if:
- Signed Informed Consent.
- Diagnosed with Diabetes.
- An Active Diabetic Ulcer larger than 5 cm2
- Sufficient limb perfusion.(e.g no compartment syndrome ankle Brachial Index (ABI)\>=0.5
You may not qualify if:
- Pregnancy.
- The patient is under another research protocol.
- One of the following:
- A. ABI\<0.5 C.Significant Arterial-Venous injury. D. Lymphedema.
- The patient underwent Chemotherapy or Radiotherapy 60 days or less prior to recruitment date.
- Sufficient Noncompliant.
- Sickle Cell Anemia, HIV, Immunodeficiency, HgB Anemia, DVT, Chronic Renal Failure, Systemic use of Steroids
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
September 4, 2011
First Posted
December 26, 2011
Study Start
January 1, 2012
Primary Completion
January 1, 2013
Study Completion
January 1, 2015
Last Updated
December 26, 2011
Record last verified: 2011-08